A7C71CEF-A5C7-4BAC-9090-9808B029190B
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 26.281208935611037
- age_years
- 39
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.509
- TGF_BETA_SIGNALING+0.502
- PROTEIN_SECRETION+0.499
- TNFA_SIGNALING_VIA_NFKB+0.477
- MYC_TARGETS_V1+0.470
- UNFOLDED_PROTEIN_RESPONSE+0.456
- ANDROGEN_RESPONSE+0.436
- OXIDATIVE_PHOSPHORYLATION+0.431
- APOPTOSIS+0.420
- MTORC1_SIGNALING+0.414
Top 10 suppressed
- KRAS_SIGNALING_DN-0.374
- SPERMATOGENESIS-0.191
- MYOGENESIS-0.128
- PANCREAS_BETA_CELLS-0.002
- APICAL_SURFACE+0.019
- APICAL_JUNCTION+0.051
- CHOLESTEROL_HOMEOSTASIS+0.136
- PEROXISOME+0.151
- COAGULATION+0.170
- WNT_BETA_CATENIN_SIGNALING+0.178
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 443B59BB-0BFD-459A-896E-FA07AA6C3A45 | — | — | 0.940 |
| 2 | CE7A3262-C48A-43BF-941C-9D2482B9CACD | — | — | 0.938 |
| 3 | A061C2FD-B726-422D-9470-43249B49F5BD | — | — | 0.935 |
| 4 | 228C2042-804C-47FA-B565-1993E1015D40 | — | — | 0.934 |
| 5 | 928D2F99-A86B-47CA-A961-A8CAE7B44E78 | — | — | 0.932 |
| 6 | BS_SB12W1XT | high-grade glioma | — | 0.932 |
| 7 | 8976C50F-B340-488D-B9C1-12CCAC780397 | — | — | 0.931 |
| 8 | 825AC0F8-4D16-4109-AA6A-4648934E3C35 | — | — | 0.930 |
| 9 | ED604501-C110-4693-820B-DE9FB648FEAA | — | — | 0.929 |
| 10 | DD203D19-D635-4112-AF75-9724E0A64A0B | — | — | 0.929 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 46 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.509 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.502 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.499 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.477 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.470 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.456 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.436 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.431 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.420 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.414 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.395 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.391 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.379 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.363 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.361 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.343 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.341 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.329 | Inavolisib | — uncovered |
| COMPLEMENT | 0.323 | Inavolisib | — uncovered |